**Name of Journal:** *World Journal of Virology*

**ESPS Manuscript NO:** 1371

**Columns: TOPIC HIGHLIGHT**

**Gualtiero Alvisi, PhD, Assistant Professor,** *Series Editor*

**Viral proteins and Src family kinases: mechanisms of pathogenicity from a “liaison dangereuse”**

Pagano MA *et al*. Viral proteins hijacking SFKs

Mario Angelo Pagano, Elena Tibaldi, Giorgio Palù, Anna Maria Brunati

**Mario Angelo Pagano, Elena Tibaldi, Giorgio Palù, Anna Maria Brunati** Department of Molecular Medicine, University of Padua, Padua 35121, Italy

**Author contributions**: Pagano MA, Tibaldi E, Palù G and Brunati AM solely contributed to this paper.

**Correspondence to: Anna Maria Brunati**, **Professor,** Department of Molecular Medicine, University of Padua, Viale G. Colombo 3, Padua 35131, Italy. alberto.bindoli@bio.unipd.it

**Telephone:** +39-049-8276114 **Fax:** +39-049-8073310

**Received:** December 5, 2012 **Revised:** January 7, 2012

**Accepted:** January 23, 2013

**Published online:**

**Abstract**

To complete their life cycle and spread, viruses interfere with and gain control of diverse cellular processes, this most often occurring through interaction between viral proteins and resident protein partners. Among the latter, Src family kinases (SFKs), a class of non-receptor tyrosine kinases that contribute to the conversion of extracellular signals into intracellular signalling cascades and are involved in virtually all cellular processes, have recently emerged as critical mediators between the cell’s infrastructure and the viral demands. In this scenario, structural or ex novo synthesized viral proteins are able to bind to the different domains of these enzymes through specific short linear motifs present along their sequences. Proline-rich motifs displaying the conserved minimal consensus PxxP and recognizing the SFK SH3 domain constitute a cardinal signature for the formation of multiprotein complexes and this interaction may promote phosphorylation of viral proteins by SFKs, thus creating phosphotyrosine motifs that become docking site for the SH2 domains of SFKs or other SH2 domain-bearing signaling molecules. Importantly, the formation of these assemblies also results in a change in the activity and/or location of SFKs, and these events are critical in perturbing key signaling pathways so that viruses can utilize the cell’s machinery to their own benefit. In the light of these observations, although viral proteins as such, especially those with enzyme activity, are still regarded as valuable targets for therapeutic strategies, multiprotein complexes composed of viral and host cell proteins are increasingly becoming objects of investigation in a view to deeply characterize the structural aspects that favor their formation and to develop new compounds able to contrast viral diseases in an alternative manner.

**Key words:** Interaction; Phosphotyrosine; Proline-rich motif; SH2 domain; SH3 domain

© 2013 Baishideng. All rights reserved.

Pagano MA, Tibaldi E, Palù G, Brunati AM. Viral proteins and Src family kinases: mechanisms of pathogenicity from a “liaison dangereuse”.

**INTRODUCTION**

Though not strictly meeting the definition of living organisms, viruses can replicate and spread, provided that they infect host cells where to produce a new offspring. In this regard, viruses are obligate intracellular parasites that have evolved complex strategies to complete their life cycle consisting in contrasting and even evading innate defense mechanisms of the host cell for which they have a tropism so as to take control over key cell pathways[1,2]. Therefore, they interfere with the diverse cellular processes, especially those involving replication of genetic material, protein translation and trafficking, with viral structural and non-structural proteins undergoing post-translational modifications, such as phosphorylation, ubiquitination, glycosylation and cleavage prior to or after interacting with a vast part of the host’s proteome, thereby forming new multiprotein assemblies[2]. Indeed, much effort has been made in the last few decades to dissect the cellular signaling pathways hijacked by viruses and the underlying molecular mechanisms, leading to the identification of several host cell factors playing a major role in the viral life cycle. Among these, Src Family Kinases (SFKs), a class of non-receptor tyrosine kinases comprising eight members (Src, Yes, Fyn, Fgr, Lyn, Hck, Lck and Blk), have emerged as critical mediators between the cell infrastructure and the viral demands. Though being traditionally known as molecular switches situated right beneath the plasma membrane, therefrom relaying extracellular cues and governing signal transduction, SFKs localize to virtually all the other cell compartments, thereby regulating a wide spectrum of cellular processes such as growth, viability, cell cycle and metabolism[3,4] To gain a deeper understanding of how SFKs exert their function, and how viruses can benefit from the interplay with SFKs, it is necessary to bear in mind the complexity of the multidomain organization and the mechanisms of activation of SFKs themselves. From the N- to the C-terminus, their structure consists of (1) the Src Homology (SH) 4 domain, a unique region that becomes myristoylated and/or palmitoylated for membrane association of SFKs; (2) the SH3 domain, which binds specific proline-rich motifs (PRMs); (3) the SH2 domain, which recognizes phosphotyrosine motifs; (4) the SH2-kinase linker; (5) a catalytic SH1 domain; and followed by (6) a C-terminal tail implicated in the downregulation of SFKs (Figure 1). The activity of SFKs is mainly modulated by the phosphorylation state of 2 critical tyrosine residues, Tyr416 and Tyr527 (based on the amino acid numbering of chicken c-Src and corresponding to Tyr419 and Tyr530 in human) with opposing effects: the former, which lies in the activation loop, is subjected to autophosphorylation when the SFK is activated, whereas the latter is targeted by C-Src tyrosine Kinase (CSK)[5], resulting in the inactivation of the tyrosine kinase. The latter event is induced by an closed conformation of the SFK through 2 major intramolecular inhibitory interactions, binding of the C-terminal phosphotyrosine (Tyr527) itself to the SH2 domain, and interaction of a polyproline type II helical motif (PPII) in the SH2-kinase linker with the SH3 domain. On the other hand, multiple events can induce disruption of such inhibitory mechanisms, such as dephosphorylation of the tail, with its displacement from the SH2 domain and/or displacement of the PPII motif from the SH3 domain, ultimately resulting in the full activation of SFKs[6]. All these features, either functional or structural, can be exploited one at a time or in combination by most, if not all, viruses to take over the cell machinery, from the cell entry, all through the genome replication until the release of new particles. As to internalization, viral particles induce, upon interaction of cognate membrane receptors, activation of SFKs, which, as apical cellular transducers in receptor-mediated cellular signaling, take part in the activation of clathrin-, caveolin-dependent endocytic pathways, or the alternate mechanism based upon macropinocytosis and are subsequently taken up by host cells for uncoating and genome replication[7-10]. Another different mode of viral uptake into the host cell occurs in polarized cells and is mediated by SFKs, which are activated upon virus attachment to the plasma membrane, so that tight junction barrier function is perturbed to allow viruses to reach their specific receptors at the baso-lateral side of epithelial cells. As a result, viral particles can be endocytosed[9] or participate in relocalizing viral receptors from the baso-lateral to the apical membrane surface in response to cytokines released by infected macrophages with subsequent entry into the epithelial cells[10].

Thus, regardless of the viral species, it can be stated that SFKs are involved in the cell entry of viral particles simply by “doing their duty” as component of signalosomes, that is by relaying the extracellular cues, in this case consisting in viral ligands that bind to cell receptors, to downstream effector molecules and preparing the cellular environment to take up virions by the different mechanisms of endocytosis. An actual interaction between SFKs and viral proteins (VPs) does not occur in this early phase of infection, instead taking place only after uncoating and ex novo synthesis of viral gene products. This association can be mediated by the non-catalytic (SH3 and SH2) and catalytic (SH1) domains of SFKs, thereby resulting in directing the localization or affecting the activity of SFKs themselves, in order to best support genome replication, particle assembly and spread.

This review offers a brief summary of the current knowledge of the molecular mechanisms underlying the interactions between SFKs and VPs as well as the consequences thereof, so as to highlight common or rather specific structural motifs that might become molecular targets for disrupting such associations and to provide a new perspective in managing viral infections.

**INTRACELLULAR VIRAL HIJACKING OF SFKS**

It has been largely described that a plethora of viruses, once they enter the cell, utilize SFKs to foster the different steps of the viral life cycle, although the molecular mechanisms have not been elucidated in many cases. However, accumulating evidence indicates that direct interaction of VPs with SFKs results in the activation of SFKs with subsequent (1) phosphorylation of VPs, which acquire new functional properties (Figure 2A-C), or (2) delocalization of SFKs to cell compartments targeted by specific VPs, where SFKs can exert their catalytic and non-catalytic action (Figure 2D), all these events being often well intertwined with one another. Although involved as apical molecular switches orchestrating virtually all cellular signaling pathways and sharing a highly similar structural arrangement, the single SFKs often demonstrate a differentiated responsiveness to VPs, which depends on the inbuilt properties of the kinase structure and the mode of interaction with VPs, especially with respect to the SH3 and SH2 domains, resulting in remarkably diverse effects on their non-redundant functions in a cellular scenario. This can exemplified by VPs that can activate certain SFKs, but inhibit or leave unaffected others in the same cell type, as long as they are co-expressed. Hence, this observation, if considered in the more complex framework of the virus-host relationship, may help devise therapeutic strategies aimed at developing drugs capable of selectively disrupting VP-SFK interactions without altering signaling networks essential for the host cell life.

**VPS AS SUBSTRATES FOR SFKS**

The number of tyrosine phosphorylated VPs is for the time being rather small, and these mostly include molecules from classes of viruses that can establish chronic infections, such as herpesviridae, polyomaviridade and retroviridae, among others (Table 1).

The polyoma middle-T antigen (MT), an early product of the viral lytic cycle of the polyomavirus, which is known to contribute to the onset of multiple tumors, is phosphorylated by Src and Fyn, at tyrosines that become docking sites for molecules essential for downstream signaling (*e.g.*, PLCγ, PI3K and Shc)[11]. This multiprotein complex then mimics a constantly activated growth factor receptor at the plasma membrane. Importantly, a preliminary step for SFKs to phosphorylate the MT is their activation, which occurs upon binding of their SH1 domain to the MT itself and concurrently to the dimeric core of the serine/threonine protein phosphatase 2A (PP2A), which acts as a scaffold between the MT and SFKs[12,13] (modeled in Figure 2A).

Another VP that associates to the plasma membrane and exhibits a transforming ability owing to phosphorylation by the SFK Lck is the tyrosine kinase interacting protein (Tip), an oncoprotein encoded by the genome of Herpesvirus saimiri (HVS), a T-lymphotropic monkey herpesvirus. Importantly, Lck phosphorylates Tip at different tyrosines responsible for binding the SH2 domains of various signaling molecules, among which Lck itself, STAT3 and STAT6, all required for promoting the transformed phenotype[14,15]. Also in this case, the essential requirement for phosphorylation is the initial interaction between the SFK and the substrate, here mediated by Tip’s sequence homologous to the C-terminus of SFKs and SH3-binding PRM with Lck[16]. The plasma membrane also serves as the anchoring site for VP11/12, a tegument protein residing between the capsid and the envelope of the Herpes Simplex Virus (HSV), immediately after viral entry, this VP being strongly phosphorylated by SFKs and hence modulating cellular signaling pathways[17]. Of note, the function of VP11/12 as a component of a signalosome differs from that exerted by VP11/12 itself in the virion assembly at the perinuclear cytoplasmic foci of the infected cells, whereby it also massively localizes. During T cell infection, VP11/12 behaves as an activator and a substrate of Lck, which phosphorylates VP11/12 at a number of tyrosines serving as docking sites for, at least as documented thus far, the SH2 domain of Lck itself and the phosphatidylinositol 3-kinase (PI3K) regulatory subunit p85[18]. It is to be underlined that under these conditions Lck does not operate as a transducer of TCR signaling but triggers cellular processes peculiarly directed by VP11/12, which are still being investigated. Other aspects that remain to be explored are the mechanism of Lck activation and the mode of recognition of VP11/12 as a substrate by Lck, for which, on the basis of the examples mentioned above, an interaction between linear binding motifs in VP11/12 and the non-catalytic domains of the SFK may be required. Indeed, the primary sequence of VP11/12 exhibits several PRMs, which might provide an anchorage for the SFK-SH3 domain with subsequent structural changes from the inactive close to the active open conformation of SFKs, to the catalytic pocket of which the access of VP11/12 as substrate is then favored. That phosphorylation of VPs and the interaction between specific motifs harbored by VPs and the modular domains of SFKs may be connected seems to be further confirmed by the findings regarding Vpx, an accessory protein of the human immunodeficiency virus type 2 (HIV-2) and the Simian immunodeficiency virus (SIV)[19]. This VP, which is coupled to the preintegration complex and localizes to the nuclei of infected cells, shuttles to the cytoplasm to be incorporated into the viral core and ensures efficient viral replication, only if it becomes phosphorylated by the SFK Fyn (especially at Y66, 69 and Y71)[20]. This event is made possible by a preliminary interaction between Vpx PRMs and Fyn SH3 domain, which may bring Vpx to the Fyn catalytic domain[21].

The nature of the binding of other VPs that are tyrosine phosphorylated and bind to SFKs remains unclear, requiring in-depth examination. One instance may be latent membrane protein 2A (LMP2A), a viral protein encoded by Epstein-Barr virus (EBV) genome in infected B cells, which, by sequestering proteins normally associated with the B cell receptor (BCR) in the absence of BCR-triggering antigens, mimics the latter with subsequent activation of downstream survival signaling pathways, hence altering normal B cell development[22]. In particular, it has recently ascertained that phosphorylation of LMP2A by Lyn, the most expressed SFK in B lymphocytes, exerts a dual role, namely as i) an early requirement for the formation of the LMP2A-based signalosome through creation of docking sites for the Spleen tyrosine kinase (Syk), the SH2 domain-containing adapter protein B (Shb) and Lyn itself[23], and as ii) a key regulatory event in the modulation of LMP2A-dependent signaling by degradation of various components of this multiprotein complex (Lyn and even LMP2A itself)[24]. Also in the case of LMP2A, it is not clear how Lyn becomes activated before phosphorylating the VP. In this respect, of the several PXXP motifs along the sequence of LMP2A, the N-terminal ones have only been tested for binding SH3 domains, proving unable to do so, thus leaving open the possibility that the C-terminal PPII helical motif may be a site of interaction and activation for Lyn[23] (the basic mechanisms demonstrated or thought to underlie interaction and downstream effects of Tip, VP11/12, Vpx and LMP2A with SFKs are illustrated in Figure 2B)

An even more intricate case is represented by the non-structural protein 5A (NS5A) encoded by the genome of the hepatitis c virus (HCV), which is essential for HCV replication and virion assembly in hepatocytes[25].ThisVP has recently been found to be phosphorylated at tyrosines within SH2-binding motifs, in addition to being highly phosphorylated at serine residues[26-28]. It also bears a conserved C-terminal PRM that has been shown to bind to the recombinant SH3 domains of Hck, Lck, Lyn and Fyn, but not Src, negatively affecting the activity of Hck, Lck and Lyn but stimulating that of Fyn[29] Though not binding to Src via the SH3 domain thereof, NS5A interacts with the SH2 domain of this SFK after being phosphorylated in HCV-infected hepatocytes, an event which is critical for viral replication and whereby Fyn, the only SFK activated by NS5A upon interaction mediated via SH3 domain, proves dispensable[27]. A possible mechanism for the phosphorylation of NS5A and subsequent SH2 domain-mediated interaction with Src is set forth in the next section and modeled in Figure 2C. Besides, in B cells, whereby infection by HCV causes mixed cryoglobulinemia and B cell non-Hodgkin's lymphoma, Fyn interacts with NS5A through both its SH2 and SH3 domains in a tyrosine phosphorylation-dependent manner and by recognition of a PRM of NS5A itself, respectively, resulting in inhibition of viral replication in parallel with Fyn enhanced activity[28]. These data again confirm that VPs need to specifically select SFKs, whose non-redundant functions can be exploited to dictate the different steps of viral replication.

**EFFECTS ON LOCATION AND ACTIVITY OF SFKS MEDIATED BY INTERACTION WITH VPS**

The mechanisms leading to the phosphorylation of VPs described above seem to mainly point to the earlier binding of VPs to the SH3 domain of SFKs as the activation event for SFKs themselves, the newly phosphorylated tyrosines providing an anchorage for signaling molecules utilized by the virus for its own benefit, even for SFKs among others. We shall hereafter illustrate a set of VPs that are still able to interact with the SH3 domain of SFKs and function as activators of SFKs without being their substrates (a general diagram is shown in Figure 2D). From this list, the well-characterized HIV-1 accessory protein Nef stands out, it being essential for virus replication and AIDS pathogenesis by interacting with various host cell proteins involved in immune recognition and survival, among which SFKs are targeted with high selectivity[30-32]. Among the many interaction motifs along its sequence, Nef harbors a highly conserved PxxPxR motif, which, together with a hydrophobic pocket in the core region[33] takes part in the interface between Nef and the SH3 domain of a few of SFKs, namely Hck and Lyn[33], thus causing disruption of the negative regulatory interaction between the SH2-kinase linker and the SH3 domain itself on the back of the kinase domain and subsequent activation. Of note, in spite of the high conservation of Nef’s regions for binding to these SFKs, other determinants have emerged as critical in this function and also in influencing replication of HIV-1 variants. As an example, the R71T mutation occurring immediately upstream of the PRM, has been correlated with a lower ability of Nef to bind SFKs as well as a decreased capability of the HIV-1 strain bearing this mutation of replicating[34]. At the cellular level, Nef activates and reroutes specific SFKs to the Golgi apparatus, the preferential subcellular localization of this VP, thereby optimizing the environmental conditions for viral replication and provoking severe alterations of the immune response. In macrophages, Nef is described to hijack and activate Hck, localizing it to the Golgi apparatus, and perturbing the N-glycosylation/trafficking processes by triggering the MAP kinase ERK-GRASP65 cascade[35,36]; instead, in T lymphocytes, Lck is directed by Nef from the plasma membrane to the trans-Golgi network, which prevents Lck from being recruited to the immunological synapse, whose altered formation in turn results in interfering with TCR signaling[37]. In contrast to Nef, whose role has been, and still is being, deeply explored, the pathophysiological consequences of the interaction of other VPs with SFKs are far from being totally clarified.

The non-structural 1 (NS1) protein of the avian influenza virus (AIV), a multifunctional protein with interferon-antagonistic properties, is a further example of the interaction between the SH3 domain of SFKs through PRMs of specific VPs as a means to mediate pathogenicity by viruses[38]. First being isolated in poultry and having exhibited high virulence and pathogenicity, it was also shown to cross the species barrier, involving human fatalities, especially in the Far East. The possibility that such a viral strain or new reassortants might cause severe pandemics had generated a new interest in evaluating the pathogenicity determinant in the spread and pathogenesis of the disease[39,40]. NS1 possesses two functional domains, the N-terminal RNA-binding domain containing one nuclear localization signal as well as a SH2- binding motif targetable after phosphorylation of the tyrosine residue, and the C-terminal effector domain, with two PRMs, a further nuclear localization sequence and a PDZ binding motif. Of the PRMs, the first is generally conserved in all influenza genotypes and harbors the structural determinants for binding the SH3 domain of the PI3K regulatory subunit p85 (PI/LPxxP)[41], whereas the C-terminal has a certain variability that parallels its capability of interacting with the SH3 domain of and activating the SFK Src[42]. In this respect, only NS1 bearing the consensus sequence type 2 for binding SH3 domains of Src (PXXPXK/R), was able to enhance the SFK activity, which occurred in virus genotypes that caused the most severe human influenza pandemics in 1918 and killed turkeys in Italy in 1999 with heavy economic losses, whereas the viral strains that were mutated in this region did not affect SFK activity. To date, the function of an activated form of Src in AIV-infected cells is not fully clear, even though it is thought that it may be related to the localization of the Src-NS1 complex.

Another prototype for the change in subcellular localization of SFKs induced by VPs is represented by the human T-cell leukemia virus type 1 (HTLV-1) accessory protein p13, although the data refer to experimental approaches in vitro or in cultered cells transfected with the single SFKs or p13 itself. p13 is known to localize to mitochondria thanks its N-terminal mitochondrial localization signal, where it brings about an inward K+ current across the inner mitochondrial membrane, leading to swelling, depolarization and increased respiratory chain activity[43]. Recently, p13 has been found to bind to the SH3 domain of SFKs by a well-defined C-terminal PRM and to act as a carrier for SFKs themselves into mitochondria, this new localization of SFKs resulting in i) a sharp rise in intramitochondrial tyrosine phosphorylation, and ii) a significant mitigation of p13’s aforementioned effects on mitochondria[44]. This observation seems to be in line with recent findings that strongly suggest a new role for SFKs as factors that help preserve mitochondrial structural and functional integrity under stressful conditions[45], thus further providing novel insights into the catalytic and non-catalytic role of SFKs in virus-infected cells[46,47]. The complex relationship between such functions of SFKs and the physical interaction thereof with VPs fits into another model represented by the events that lead to the formation of the HCV replication complex, in which the RNA-dependent RNA polymerase NS5B and the above mentioned substrate for SFKs, NS5A, together with the SFK Src, take part[27]. The integrity of this multimolecular complex, which is essential in HCV replication, requires Src as a scaffold for promoting a tighter interaction between NS5A and NS5B, with both the modular SH2 and SH3 domains as well as the catalytic activity of Src being implicated. Interestingly, Src is the only SFK that does not bind to NS5A through its SH3 domain[26], whereas it recognizes the C-terminal proline-rich region containing a non-canonical SH3 binding motif within NS5B[27]. On the other hand, the SH2 domain of Src interacts with a yet-to-be-identified tyrosine phosphorylated binding motif within NS5A, respectively. Although the molecular mechanism underlying the formation of the complex is unknown, it is tempting to speculate that Src stabilizes the weak interaction between NS5A and NS5B by firstly recognizing the PRM of NS5B, though it does not display an optimal consensus for binding to the SH3 domain of SFKs, thus becoming activated and enabled to phosphorylate NS5A. Phosphotyrosines on NS5A can then be targeted as docking sites by Src, further strengthening the stability of the heterotrimer (Figure 2C). What we hereby again underscore is that VPs and cellular proteins, such as SFKs, complexed into a new operative unit can serve as a key to interpreting the intricate relationship between host cells and viruses in order to elaborate novel strategies to disrupt aberrant multiprotein associations.

**CONCLUDING REMARKS AND PERSPECTIVES**

The significance of SFKs as critical mediators in the life cycle of viruses has been widely shown by the effects of the inhibition of their enzymatic activity or of their expression as well as by those related to the interaction with specific VPs, as hereby briefly reviewed. Indeed, this latter issue has become a new important field of investigation, with great efforts aiming at dissecting the structural aspects that favor such interactions, in order to develop therapeutic strategies capable of disrupting them to hamper viral replication. Although the different domains of SFKs exhibits various potential anchorage sites for VPs, including the SH2 and the catalytic domain, these preferentially target the SH3 domain of SFKs by their PRMs (usually a class II motif), which generally displays the consensus sequence PxΦPxK/R (where Φ stands for a hydrophobic residue). The PRM-bearing protein can then compete with and displaces the polyproline type II helical motif (PPII) within the SH2-kinase linker of SFKs, thus directly interacting with the SH3 domain and inducing the transition from the “closed” to the “open” conformation, with three possible outcomes, (1) altered localization of SFKs; (2) phosphorylation of the viral protein with generation of docking sites available for further interactions; and (3) hyperactivation of the kinase activity. This latter effect has been explained for Hck bound to Nef, but not thus far for other SFKs, through kinetic studies, which have highlighted that Nef’s PRM induces a change in the conformation of the active site of Hck by an allosteric mechanism with a decrease in the KM for ATP[48]. Of note, even if all SFKs share a common domain structure and a mode of regulation, VPs may display different abilities to interact with each single SFK and to affect their catalytic activity by their PRM. This wide variability in the response of the single SFKs demands a further effort to extend our knowledge on the structural determinants of the SH3 domain also outside of the interface binding the viral PRM, this possibly providing the ground for the prediction of recognition elements. In a therapeutic perspective, two main schools of thought have surfaced in addressing this issue, one arguing for the use of bioengineered polypeptides capable of interfering with SH3 binding of SFKs to VPs[49-51] and the other supporting the implementation of non-toxic kinase inhibitors that bind the catalytic groove of SFKs only if the VP:SFK complex is formed (*e.g.* Nef:Hck)[52,53]. This latter approach would be remarkably useful in preventing unpleasant or harmful side effects, since such drugs would not affect the pool of uncomplexed SFKs involved in other cellular activities.

The data hereby summarized lead us to assume that, despite the widespread occurrence of PRMs on VPs and the existence of over 200 SH3 domains, PRMs are directed to specific host targets, among which SFKs are crucial actors in sustaining virus survival[54-56] . Besides, the interaction between SFKs and PRMs of Vps seems to be emerging as a novel issue of special interest in the light of their association with virulence of viral strains and the level of pathogenicity, as reported for AIV NS1[42] and HIV-1 Nef[33,34], with the enhancement of the kinase activity being a sort of epiphenomenon related the severity of disease. In this respect, retrospective studies on highly pathogenic virosis and structural analysis of PRM-bearing proteins as well as their effect on SFKs would open new perspectives and providing further hints for pharmaceutical research and clinical applications.

**REFERENCES**

1 **Welsch S**, Locker JK. Hijacking cellular garbage cans. *Cell Host Microbe* 2010; **7**: 424-426 [PMID: 20542246 DOI: 10.1016/j.chom.2010.05.014]

2 **Culver JN**, Padmanabhan MS. Virus-induced disease: altering host physiology one interaction at a time. *Annu Rev Phytopathol* 2007; **45**: 221-243 [PMID: 17417941 DOI: 10.1146/annurev.phyto.45.062806]

3 **Ingley E**. Src family kinases: regulation of their activities, levels and identification of new pathways. *Biochim Biophys Acta* 2008; **1784**: 56-65 [PMID: 17905674 DOI: 10.1016/j.bbapap.2007.08.012]

4 **Salvi M**, Brunati AM, Bordin L, La Rocca N, Clari G, Toninello A. Characterization and location of Src-dependent tyrosine phosphorylation in rat brain mitochondria. *Biochim Biophys Acta* 2002; **1589**: 181-195 [PMID: 12007793 DOI: 10.1016/S0167-4889(02)00174-X]

5 **Parsons JT**, Weber MJ. Genetics of src: structure and functional organization of a protein tyrosine kinase. *Curr Top Microbiol Immunol* 1989; **147**: 79-127 [PMID: 2482802 DOI: 10.1007/978-3-642-74697-0\_3]

6 **Chong YP**, Ia KK, Mulhern TD, Cheng HC. Endogenous and synthetic inhibitors of the Src-family protein tyrosine kinases. *Biochim Biophys Acta* 2005; **1754**: 210-220 [PMID: 16198159 DOI: 10.1016/j.bbapap.2005.07.027]

7 **Coyne CB**, Bergelson JM. Virus-induced Abl and Fyn kinase signals permit coxsackievirus entry through epithelial tight junctions. *Cell* 2006; **124**: 119-131 [PMID: 16413486 DOI: 10.1016/j.cell.2005.10.035]

8 **Huang WR**, Wang YC, Chi PI, Wang L, Wang CY, Lin CH, Liu HJ. Cell entry of avian reovirus follows a caveolin-1-mediated and dynamin-2-dependent endocytic pathway that requires activation of p38 mitogen-activated protein kinase (MAPK) and Src signaling pathways as well as microtubules and small GTPase Rab5 protein. *J Biol Chem* 2011; **286**: 30780-30794 [PMID: 21705803 DOI: 10.1074/jbc.M111.257154]

9 **Nogalski MT**, Chan G, Stevenson EV, Gray S, Yurochko AD. Human cytomegalovirus-regulated paxillin in monocytes links cellular pathogenic motility to the process of viral entry. *J Virol* 2011; **85**: 1360-1369 [PMID: 21084488 DOI: 10.1128/JVI.02090-10]

10 **Lütschg V**, Boucke K, Hemmi S, Greber UF. Chemotactic antiviral cytokines promote infectious apical entry of human adenovirus into polarized epithelial cells. *Nat Commun* 2011; **2**: 391 [PMID: 21750545 DOI: 10.1038/ncomms1391]

11 **Courtneidge SA**, Smith AE. Polyoma virus transforming protein associates with the product of the c-src cellular gene. *Nature* ; **303**: 435-439 [PMID: 6304524 DOI: 10.1038/303435a0]

12 **Zhou AY,** Ichaso N, Adamarek A, Zila V, Forstova J, Dibb NJ, Dilworth SM. Polyomavirus middle T-antigen is a transmembrane protein that binds signaling proteins in discrete subcellular membrane sites. J Virol 2011; 85(7): 3046-3054 [DOI: 10.1128/JVI.02209-10]

13 **Schaffhausen BS**, Roberts TM. Lessons from polyoma middle T antigen on signaling and transformation: A DNA tumor virus contribution to the war on cancer. *Virology* 2009; **384**: 304-316 [PMID: 19022468 DOI: 10.1016/j.virol.2008.09.042]

14 **Bauer F**, Hofinger E, Hoffmann S, Rösch P, Schweimer K, Sticht H. Characterization of Lck-binding elements in the herpesviral regulatory Tip protein. *Biochemistry* 2004; **43**: 14932-14939 [PMID: 15554700 DOI: 10.1021/bi0485068]

15 **Kim Y**, Kwon EK, Jeon JH, So I, Kim IG, Choi MS, Kim IS, Choi JK, Jung JU, Cho NH. Activation of the STAT6 transcription factor in Jurkat T-cells by the herpesvirus saimiri Tip protein. *J Gen Virol* 2012; **93**: 330-340 [PMID: 22012462 DOI: 10.1099/vir.0.036087-0]

16 **Romir J**, Lilie H, Egerer-Sieber C, Bauer F, Sticht H, Muller YA. Crystal structure analysis and solution studies of human Lck-SH3; zinc-induced homodimerization competes with the binding of proline-rich motifs. *J Mol Biol* 2007; **365**: 1417-1428 [PMID: 17118402 DOI: 10.1016/j.jmb.2006.10.058]

17 **Zahariadis G**, Wagner MJ, Doepker RC, Maciejko JM, Crider CM, Jerome KR, Smiley JR. Cell-type-specific tyrosine phosphorylation of the herpes simplex virus tegument protein VP11/12 encoded by gene UL46. *J Virol* 2008; **82**: 6098-6108 [PMID: 18417566 DOI: 10.1128/JVI.02121-07]

18 **Wagner MJ**, Smiley JR. Herpes simplex virus requires VP11/12 to activate Src family kinase-phosphoinositide 3-kinase-Akt signaling. *J Virol* 2011; **85**: 2803-2812 [PMID: 21228233 DOI: 10.1128/JVI.01877-10]

19 **Planelles V**, Barker E. Roles of Vpr and Vpx in modulating the virus-host cell relationship. *Mol Aspects Med* 2010; **31**: 398-406 [PMID: 20558198 DOI: 10.1016/j.mam.2010.05.002]

20 **Singhal PK**, Rajendra Kumar P, Subba Rao MR, Mahalingam S. Nuclear export of simian immunodeficiency virus Vpx protein. *J Virol* 2006; **80**: 12271-12282 [PMID: 16987982 DOI: 10.1128/JVI.00563-06]

21 **Pancio HA**, Vander Heyden N, Ratner L. The C-terminal proline-rich tail of human immunodeficiency virus type 2 Vpx is necessary for nuclear localization of the viral preintegration complex in nondividing cells. *J Virol* 2000; **74**: 6162-6167 [PMID: 10846100 DOI: 10.1128/JVI.74.13.6162-6167.2000]

22 **Fruehling S**, Swart R, Dolwick KM, Kremmer E, Longnecker R. Tyrosine 112 of latent membrane protein 2A is essential for protein tyrosine kinase loading and regulation of Epstein-Barr virus latency. *J Virol* 1998; **72**: 7796-7806 [PMID: 9733815]

23 **Dergai O**, Dergai M, Skrypkina I, Matskova L, Tsyba L, Gudkova D, Rynditch A. The LMP2A protein of Epstein-Barr virus regulates phosphorylation of ITSN1 and Shb adaptors by tyrosine kinases. *Cell Signal* 2013; **25**: 33-40 [PMID: 22975684 DOI: 10.1016/j.cellsig.2012.09.011]

24 **Rovedo M**, Longnecker R. Epstein-Barr virus latent membrane protein 2A preferentially signals through the Src family kinase Lyn. *J Virol* 2008; **82**: 8520-8528 [PMID: 18579586 DOI: 10.1128/JVI.00843-08]

25 **Macdonald A**, Harris M. Hepatitis C virus NS5A: tales of a promiscuous protein. *J Gen Virol* 2004; **85**: 2485-2502 [PMID: 15302943 DOI: 10.1099/vir.0.80204-0]

26 **Macdonald A**, Crowder K, Street A, McCormick C, Harris M. The hepatitis C virus NS5A protein binds to members of the Src family of tyrosine kinases and regulates kinase activity. *J Gen Virol* 2004; **85**: 721-729 [PMID: 14993658 DOI: 10.1099/vir.0.19691-0]

27 **Pfannkuche A**, Büther K, Karthe J, Poenisch M, Bartenschlager R, Trilling M, Hengel H, Willbold D, Häussinger D, Bode JG. c-Src is required for complex formation between the hepatitis C virus-encoded proteins NS5A and NS5B: a prerequisite for replication. *Hepatology* 2011; **53**: 1127-1136 [PMID: 21480319 DOI: 10.1002/hep.24214]

28 **Nakashima K**, Takeuchi K, Chihara K, Horiguchi T, Sun X, Deng L, Shoji I, Hotta H, Sada K. HCV NS5A protein containing potential ligands for both Src homology 2 and 3 domains enhances autophosphorylation of Src family kinase Fyn in B cells. *PLoS One* 2012; **7**: e46634 [PMID: 23077515 DOI: 10.1371/journal.pone.0046634]

29 **Shelton H**, Harris M. Hepatitis C virus NS5A protein binds the SH3 domain of the Fyn tyrosine kinase with high affinity: mutagenic analysis of residues within the SH3 domain that contribute to the interaction. *Virol J* 2008; **5**: 24 [PMID: 18267011 DOI: 10.1186/1743-422X-5-24]

30 **Fackler OT**, Baur AS. Live and let die: Nef functions beyond HIV replication. *Immunity* 2002; **16**: 493-497 [PMID: 11970873 DOI: 10.1016/S1074-7613(02)00307-2]

31 **Moarefi I**, LaFevre-Bernt M, Sicheri F, Huse M, Lee CH, Kuriyan J, Miller WT. Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. *Nature* 1997; **385**: 650-653 [PMID: 9024665 DOI: 10.1038/385650a0]

32 **Alvarado JJ**, Betts L, Moroco JA, Smithgall TE, Yeh JI. Crystal structure of the Src family kinase Hck SH3-SH2 linker regulatory region supports an SH3-dominant activation mechanism. *J Biol Chem* 2010; **285**: 35455-35461 [PMID: 20810664 DOI: 10.1074/jbc.M110.145102]

33 **Lee CH**, Saksela K, Mirza UA, Chait BT, Kuriyan J. Crystal structure of the conserved core of HIV-1 Nef complexed with a Src family SH3 domain. *Cell* 1996; **85**: 931-942 [PMID: 8681387 DOI: 10.1016/S0092-8674(00)81276-3]

34 **Grzesiek S**, Bax A, Clore GM, Gronenborn AM, Hu JS, Kaufman J, Palmer I, Stahl SJ, Wingfield PT. The solution structure of HIV-1 Nef reveals an unexpected fold and permits delineation of the binding surface for the SH3 domain of Hck tyrosine protein kinase. *Nat Struct Biol* 1996; **3**: 340-345 [PMID: 8599760 DOI: 10.1038/nsb0496-340]

35 **Hassan R**, Suzu S, Hiyoshi M, Takahashi-Makise N, Ueno T, Agatsuma T, Akari H, Komano J, Takebe Y, Motoyoshi K, Okada S. Dys-regulated activation of a Src tyroine kinase Hck at the Golgi disturbs N-glycosylation of a cytokine receptor Fms. *J Cell Physiol* 2009; **221**: 458-468 [PMID: 19585521 DOI: 10.1002/jcp.21878]

36 **Hiyoshi M**, Takahashi-Makise N, Yoshidomi Y, Chutiwitoonchai N, Chihara T, Okada M, Nakamura N, Okada S, Suzu S. HIV-1 Nef perturbs the function, structure, and signaling of the Golgi through the Src kinase Hck. *J Cell Physiol* 2012; **227**: 1090-1097 [PMID: 21567396 DOI: 10.1002/jcp.22825]

37 **Pan X**, Rudolph JM, Abraham L, Habermann A, Haller C, Krijnse-Locker J, Fackler OT. HIV-1 Nef compensates for disorganization of the immunological synapse by inducing trans-Golgi network-associated Lck signaling. *Blood* 2012; **119**: 786-797 [PMID: 22123847 DOI: 10.1182/blood-2011-08-373209]

38 **Hale BG**, Randall RE, Ortín J, Jackson D. The multifunctional NS1 protein of influenza A viruses. *J Gen Virol* 2008; **89**: 2359-2376 [PMID: 18796704 DOI: 10.1099/vir.0.2008/004606-0]

39 **Hale BG**, Steel J, Manicassamy B, Medina RA, Ye J, Hickman D, Lowen AC, Perez DR, García-Sastre A. Mutations in the NS1 C-terminal tail do not enhance replication or virulence of the 2009 pandemic H1N1 influenza A virus. *J Gen Virol* 2010; **91**: 1737-1742 [PMID: 20237225 DOI: 10.1099/vir.0.020925-0]

40 **Hale BG**, Steel J, Medina RA, Manicassamy B, Ye J, Hickman D, Hai R, Schmolke M, Lowen AC, Perez DR, García-Sastre A. Inefficient control of host gene expression by the 2009 pandemic H1N1 influenza A virus NS1 protein. *J Virol* 2010; **84**: 6909-6922 [PMID: 20444891 DOI: 10.1128/JVI.00081-10]

41 **Zhang DG**, Li WZ, Wang GF, Su Y, Zeng J, Zhang C, Zeng XX, Chen XX, Xu YX, Li KS. Heterologous SH3-p85beta inhibits influenza A virus replication. *Virol J* 2010; **7**: 170 [PMID: 20653952 DOI: 10.1186/1743-422X-7-170]

42 **Bavagnoli L**, Dundon WG, Garbelli A, Zecchin B, Milani A, Parakkal G, Baldanti F, Paolucci S, Volmer R, Tu Y, Wu C, Capua I, Maga G. The PDZ-ligand and Src-homology type 3 domains of epidemic avian influenza virus NS1 protein modulate human Src kinase activity during viral infection. *PLoS One* 2011; **6**: e27789 [PMID: 22110760 DOI: 10.1371/journal.pone.0027789]

43 **Silic-Benussi M**, Biasiotto R, Andresen V, Franchini G, D'Agostino DM, Ciminale V. HTLV-1 p13, a small protein with a busy agenda. *Mol Aspects Med* 2010; **31**: 350-358 [PMID: 20332002 DOI: 10.1016/j.mam.2010.03.001]

44 **Tibaldi E**, Venerando A, Zonta F, Bidoia C, Magrin E, Marin O, Toninello A, Bordin L, Martini V, Pagano MA, Brunati AM. Interaction between the SH3 domain of Src family kinases and the proline-rich motif of HTLV-1 p13: a novel mechanism underlying delivery of Src family kinases to mitochondria. *Biochem J* 2011; **439**: 505-516 [PMID: 21732913 DOI: 10.1042/BJ20101650]

45 **Gringeri E**, Carraro A, Tibaldi E, D'Amico FE, Mancon M, Toninello A, Pagano MA, Vio C, Cillo U, Brunati AM. Lyn-mediated mitochondrial tyrosine phosphorylation is required to preserve mitochondrial integrity in early liver regeneration. *Biochem J* 2010; **425**: 401-412 [PMID: 19832701 DOI: 10.1042/BJ20090902]

46 **Obata Y**, Fukumoto Y, Nakayama Y, Kuga T, Dohmae N, Yamaguchi N. The Lyn kinase C-lobe mediates Golgi export of Lyn through conformation-dependent ACSL3 association. *J Cell Sci* 2010; **123**: 2649-2662 [PMID: 20605918 DOI: 10.1242/jcs.066266]

47 **García-Martínez JM**, Calcabrini A, González L, Martín-Forero E, Agulló-Ortuño MT, Simon V, Watkin H, Anderson SM, Roche S, Martín-Pérez J. A non-catalytic function of the Src family tyrosine kinases controls prolactin-induced Jak2 signaling. *Cell Signal* 2010; **22**: 415-426 [PMID: 19892015 DOI: 10.1016/j.cellsig.2009.10.013]

48 **Pene-Dumitrescu T**, Shu ST, Wales TE, Alvarado JJ, Shi H, Narute P, Moroco JA, Yeh JI, Engen JR, Smithgall TE. HIV-1 Nef interaction influences the ATP-binding site of the Src-family kinase, Hck. *BMC Chem Biol* 2012; **12**: 1 [PMID: 22420777 DOI: 10.1186/1472-6769-12-1]

49 **Hiipakka M**, Huotari P, Manninen A, Renkema GH, Saksela K. Inhibition of cellular functions of HIV-1 Nef by artificial SH3 domains. *Virology* 2001; **286**: 152-159 [PMID: 11448168 DOI: 10.1006/viro.2001.0973]

50 **Breuer S**, Schievink SI, Schulte A, Blankenfeldt W, Fackler OT, Geyer M. Molecular design, functional characterization and structural basis of a protein inhibitor against the HIV-1 pathogenicity factor Nef. *PLoS One* 2011; **6**: e20033 [PMID: 21625496 DOI: 10.1371/journal.pone.0020033]

51 **Bouchet J**, Basmaciogullari SE, Chrobak P, Stolp B, Bouchard N, Fackler OT, Chames P, Jolicoeur P, Benichou S, Baty D. Inhibition of the Nef regulatory protein of HIV-1 by a single-domain antibody. *Blood* 2011; **117**: 3559-3568 [PMID: 21292773 DOI: 10.1182/blood-2010-07-296749]

52 **Emert-Sedlak L**, Kodama T, Lerner EC, Dai W, Foster C, Day BW, Lazo JS, Smithgall TE. Chemical library screens targeting an HIV-1 accessory factor/host cell kinase complex identify novel antiretroviral compounds. *ACS Chem Biol* 2009; **4**: 939-947 [PMID: 19807124 DOI: 10.1021/cb900195c]

53 **Dikeakos JD**, Atkins KM, Thomas L, Emert-Sedlak L, Byeon IJ, Jung J, Ahn J, Wortman MD, Kukull B, Saito M, Koizumi H, Williamson DM, Hiyoshi M, Barklis E, Takiguchi M, Suzu S, Gronenborn AM, Smithgall TE, Thomas G. Small molecule inhibition of HIV-1-induced MHC-I down-regulation identifies a temporally regulated switch in Nef action. *Mol Biol Cell* 2010; **21**: 3279-3292 [PMID: 20702582 DOI: 10.1091/mbc.E10-05-0470]

54 **Kärkkäinen S**, Hiipakka M, Wang JH, Kleino I, Vähä-Jaakkola M, Renkema GH, Liss M, Wagner R, Saksela K. Identification of preferred protein interactions by phage-display of the human Src homology-3 proteome. *EMBO Rep* 2006; **7**: 186-191 [PMID: 16374509 DOI: 10.1038/sj.embor.7400596]

55 **Carducci M**, Licata L, Peluso D, Castagnoli L, Cesareni G. Enriching the viral-host interactomes with interactions mediated by SH3 domains. *Amino Acids* 2010; **38**: 1541-1547 [PMID: 19882298 DOI: 10.1007/s00726-009-0375-z]

56 **Ren X,** Hurley JH. Proline-rich regions and motifs in trafficking: from ESCRT interaction to viral exploitation. Traffic 2011; 12(10): 1282-1290 [PMDI: 21518163 DOI: 10.1111/j.1600-0854.2011.01208.x]

**P-reviewe**r: Choi TJ; Liu XY


**S-Editor** Jiang L **L-Editor E-Editor**


**Table 1 List of the viral proteins described in this review**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Protein** |  | **Virus** | |  | **Src family kinase** |  | **Phosphorylation sites (tyrosines)** |
|  |  | |  |  |  |  |  |
| Polyoma middle-T (MT) antigen |  | | Polyomavirus |  | Src and Fyn |  | Y250, Y315 and Y322 |
|  |  | |  |  |  |  |  |
| Tyrosine kinase Interacting Protein (Tip) |  | | Herpesvirus saimiri (HVS) |  | Lck |  | Y114 and Y127 |
|  |  | |  |  |  |  |  |
| Tegument protein VP11/12, |  | | Herpes Simplex Virus (HSV) |  | Lck |  | Y not identified |
|  |  | |  |  |  |  |  |
| Accessory viral protein X (Vpx) |  | | Human Immunodeficiency Viruses (HIVs), and Simian Immunodeficiency Viruses (SIVs) |  | Fyn |  | Y66, Y69 and Y71 |
|  |  | |  |  |  |  |  |
| Latent membrane protein 2A (LMP2A) |  | | Epstein-Barr virus (EBV) |  | Lyn |  | Y74 and Y85 |
|  |  | |  |  |  |  |  |
| Non-structural protein 5A (NS5A) |  | | Hepatitis C virus (HCV) |  | Src |  | Y not identified |
|  |  | |  |  |  |  |  |
| Accessory protein Nef |  | | Human immunodeficiency viruse-1 (HIV-1), |  | SFKs |  | none |
|  |  | |  |  |  |  |  |
| Non-Structural 1 (NS1) |  | | Avian influenza virus (AIV) |  | Src |  | none |
|  |  | |  |  |  |  |  |
| Accessory protein p13 |  | | Human T-cell Leukemia Virus type 1 (HTLV-1) |  | SFKs |  | none |
|  |  | |  |  |  |  |  |
| RNA-dependent RNA polymerase NS5B |  | | Hepatitis C virus (HCV) |  | Src |  | none |

**Figure 1 Diagram representing the domain organization of** **Src family kinases.** As reported in the text, the C-terminus (C-t in the figure) when phosphorylated at Tyr527 binds to the SH2 domain and the PPII motif in the SH2 kinase linker (SH2-KL in the figure) engages the SH3 domain, thus inducing an inactive conformation. Disruption of these inhibitory interactions, in the case of viruses mostly induced by proteins bearing tyrosine phosphorylated or proline-rich motifs, leads to the full activation of SFKs.

**Figure 2 Models of mechanisms connecting viral proteins and Src family kinases and downstream effects.** Viral proteins bind to the various modular domains of Src family kinases (SFKs), with (A) or without (B-D) concurrent association with other host proteins, resulting in the subsequent phosphorylation of the VPs by which they are engaged (A-B), ultimately conferring new functional properties to VPs, or of different VPs to stabilize multiprotein complexes (C); Moreover, VPs may delocalize SFKs to different cell compartments, where SFKs in the activated form can process local substrates or act as non-catalytic mediators of the action of VPs themselves (D) (See text for further details regarding how specific VPs fit into each model. HP, host protein; pY, phosphotyrosine). Solid line, binding; arrow, downstream event.





**Figure 2**